353 related articles for article (PubMed ID: 28122581)
1. Acute myeloid leukemia - strategies and challenges for targeting oncogenic Hedgehog/GLI signaling.
Aberger F; Hutterer E; Sternberg C; Del Burgo PJ; Hartmann TN
Cell Commun Signal; 2017 Jan; 15(1):8. PubMed ID: 28122581
[TBL] [Abstract][Full Text] [Related]
2. Hedgehog/GLI signaling in tumor immunity - new therapeutic opportunities and clinical implications.
Grund-Gröschke S; Stockmaier G; Aberger F
Cell Commun Signal; 2019 Dec; 17(1):172. PubMed ID: 31878932
[TBL] [Abstract][Full Text] [Related]
3. Targeting GLI Transcription Factors in Cancer.
Didiasova M; Schaefer L; Wygrecka M
Molecules; 2018 Apr; 23(5):. PubMed ID: 29695137
[TBL] [Abstract][Full Text] [Related]
4. Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment.
Terao T; Minami Y
Cells; 2019 Apr; 8(4):. PubMed ID: 30987263
[TBL] [Abstract][Full Text] [Related]
5. Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia.
Latuske EM; Stamm H; Klokow M; Vohwinkel G; Muschhammer J; Bokemeyer C; Jücker M; Kebenko M; Fiedler W; Wellbrock J
Oncotarget; 2017 Apr; 8(17):29187-29201. PubMed ID: 28418873
[TBL] [Abstract][Full Text] [Related]
6. Targeting non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex improves the efficacy of HEDGEHOG pathway inhibition in melanoma.
Pietrobono S; Gaudio E; Gagliardi S; Zitani M; Carrassa L; Migliorini F; Petricci E; Manetti F; Makukhin N; Bond AG; Paradise BD; Ciulli A; Fernandez-Zapico ME; Bertoni F; Stecca B
Oncogene; 2021 Jun; 40(22):3799-3814. PubMed ID: 33958721
[TBL] [Abstract][Full Text] [Related]
7. Targeting cancer hallmark vulnerabilities in hematologic malignancies by interfering with Hedgehog/GLI signaling.
Krenn PW; Aberger F
Blood; 2023 Dec; 142(23):1945-1959. PubMed ID: 37595276
[TBL] [Abstract][Full Text] [Related]
8. Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC-202 blocks oncogenic hedgehog-GLI signaling and overcomes smoothened inhibitor resistance.
Gruber W; Peer E; Elmer DP; Sternberg C; Tesanovic S; Del Burgo P; Coni S; Canettieri G; Neureiter D; Bartz R; Kohlhof H; Vitt D; Aberger F
Int J Cancer; 2018 Mar; 142(5):968-975. PubMed ID: 29055107
[TBL] [Abstract][Full Text] [Related]
9. Targeting GLI1 Suppresses Cell Growth and Enhances Chemosensitivity in CD34+ Enriched Acute Myeloid Leukemia Progenitor Cells.
Long B; Wang LX; Zheng FM; Lai SP; Xu DR; Hu Y; Lin DJ; Zhang XZ; Dong L; Long ZJ; Tong XZ; Liu Q
Cell Physiol Biochem; 2016; 38(4):1288-302. PubMed ID: 27008269
[TBL] [Abstract][Full Text] [Related]
10. Hedgehog signaling and the Gli code in stem cells, cancer, and metastases.
Ruiz i Altaba A
Sci Signal; 2011 Nov; 4(200):pt9. PubMed ID: 22114144
[TBL] [Abstract][Full Text] [Related]
11. The GLI genes as the molecular switch in disrupting Hedgehog signaling in colon cancer.
Mazumdar T; DeVecchio J; Agyeman A; Shi T; Houghton JA
Oncotarget; 2011 Aug; 2(8):638-45. PubMed ID: 21860067
[TBL] [Abstract][Full Text] [Related]
12. Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects.
Wellbrock J; Latuske E; Köhler J; Wagner K; Stamm H; Vettorazzi E; Vohwinkel G; Klokow M; Uibeleisen R; Ehm P; Riecken K; Loges S; Thol F; Schubert C; Amling M; Jücker M; Bokemeyer C; Heuser M; Krauter J; Fiedler W
Clin Cancer Res; 2015 May; 21(10):2388-98. PubMed ID: 25745035
[TBL] [Abstract][Full Text] [Related]
13. β-arrestin1-mediated acetylation of Gli1 regulates Hedgehog/Gli signaling and modulates self-renewal of SHH medulloblastoma cancer stem cells.
Miele E; Po A; Begalli F; Antonucci L; Mastronuzzi A; Marras CE; Carai A; Cucchi D; Abballe L; Besharat ZM; Catanzaro G; Infante P; Di Marcotullio L; Canettieri G; De Smaele E; Screpanti I; Locatelli F; Ferretti E
BMC Cancer; 2017 Jul; 17(1):488. PubMed ID: 28716052
[TBL] [Abstract][Full Text] [Related]
14. Mitogen-activated protein kinases and Hedgehog-GLI signaling in cancer: A crosstalk providing therapeutic opportunities?
Rovida E; Stecca B
Semin Cancer Biol; 2015 Dec; 35():154-67. PubMed ID: 26292171
[TBL] [Abstract][Full Text] [Related]
15. Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia.
Kern D; Regl G; Hofbauer SW; Altenhofer P; Achatz G; Dlugosz A; Schnidar H; Greil R; Hartmann TN; Aberger F
Oncogene; 2015 Oct; 34(42):5341-51. PubMed ID: 25639866
[TBL] [Abstract][Full Text] [Related]
16. Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia.
Shallis RM; Bewersdorf JP; Boddu PC; Zeidan AM
Expert Rev Anticancer Ther; 2019 Aug; 19(8):717-729. PubMed ID: 31422721
[No Abstract] [Full Text] [Related]
17. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
[TBL] [Abstract][Full Text] [Related]
18. DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance.
Gruber W; Hutzinger M; Elmer DP; Parigger T; Sternberg C; Cegielkowski L; Zaja M; Leban J; Michel S; Hamm S; Vitt D; Aberger F
Oncotarget; 2016 Feb; 7(6):7134-48. PubMed ID: 26784250
[TBL] [Abstract][Full Text] [Related]
19. Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene.
Masetti R; Bertuccio SN; Astolfi A; Chiarini F; Lonetti A; Indio V; De Luca M; Bandini J; Serravalle S; Franzoni M; Pigazzi M; Martelli AM; Basso G; Locatelli F; Pession A
J Hematol Oncol; 2017 Jan; 10(1):26. PubMed ID: 28109323
[TBL] [Abstract][Full Text] [Related]
20. GLI transcriptional repression is inert prior to Hedgehog pathway activation.
Lex RK; Zhou W; Ji Z; Falkenstein KN; Schuler KE; Windsor KE; Kim JD; Ji H; Vokes SA
Nat Commun; 2022 Feb; 13(1):808. PubMed ID: 35145123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
